argenx SE traded at 695.60 this Friday February 6th, decreasing 20.40 or 2.85 percent since the previous trading session. Looking back, over the last four weeks, argenx SE lost 1.08 percent. Over the last 12 months, its price rose by 10.06 percent. Looking ahead, we forecast argenx SE to be priced at 686.63 by the end of this quarter and at 637.58 in one year, according to Trading Economics global macro models projections and analysts expectations.
argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.